Forus raises $150M Series C at $3B valuation — its AI network for medicine now reaches 85% of US ZIP codes

Forus raises $150M Series C at $3B valuation

Four months after debuting publicly at a $1B valuation, Forus has closed a $150M Series C at a $3B valuation. The speed of that re-rating reflects genuine scale: the company now supports millions of patients across all 50 states, reaches doctors and patients in 85% of US residential ZIP codes, and works with 9 of the top 15 global biopharma companies.

What Forus actually does

Sahir Jaggi's core argument is that AI drug discovery gets most of the attention but solves only the first problem. Turning a molecule into an approved medicine still takes more than a decade and billions of dollars — and the bottleneck is everything that comes after discovery: clinical trial recruitment, physician targeting, coverage and distribution, and post-market surveillance. Forus positions itself as the connective tissue across all of those steps.

The platform works because it sees the full process rather than a slice of it. Jaggi says that for a new autoimmune drug that came to market earlier this year, 40% of all patients who have ever taken that drug came through Forus's platform. The FDA doesn't have that visibility. Neither does the drug's manufacturer. That data advantage lets Forus tell pharma companies not just how to move faster, but where a medicine is getting stuck — which is the harder and more valuable problem.

“We're announcing our $150,000,000 Series C at a $3,000,000,000 valuation. We're now supporting millions of people across all 50 states, already used by patients in 85% of US residential ZIP codes, and working with nine of the top 15 global biopharma companies... A new drug that came out in March for an autoimmune disease — forty percent of all people who have ever taken that drug came through our platform.”

The economic thesis

The goal is not incremental efficiency. Jaggi argues that if you can make drug development faster, cheaper, and more predictable simultaneously, you change the economics of building medicines at scale. More compounds can clear the commercial hurdle, which means more drugs reach patients. He uses the film industry as the analogy: thousands of screenplays exist, but the number that become released films is tiny. The bottleneck he's targeting is the equivalent of that production and distribution gap.

Oscar Health as foundation

Jaggi traces the intellectual origins of Forus to his time at Oscar Health, where he says the central lesson was how much fragmentation and heterogeneity the healthcare system contains. No single player could track what was happening end-to-end, let alone control it. Every doctor's office runs different systems, every insurer has different rules, every drug has different coverage and distribution requirements, and every patient has a different financial and clinical profile. That complexity, which previously made the problem nearly unwritable, is what makes it well-suited to agents — and it's what gives Forus its position: being the first company to see and manage the full process creates market power that historically sat only with insurers and hospital systems.

Pharma's PR problem

Jaggi notes a sharp irony: the pharma industry has among the worst public reputations in business at the same moment that AI labs are publicly declaring they want to cure cancer — essentially aspiring to become more like pharma. He says a top-10 pharma CEO told him recently that the industry needs to reclaim its own story. GLP-1 drugs are the clearest example; Jaggi argues their impact is still underrated publicly even as bariatric surgery has been functionally displaced as a specialty.